Skip to main content

The CIPPRT is led by Professor Paramala Santosh and the team’s main research focus is on translational research, exploring new ways to improve patient care, psychopharmacology, clinical trials in Rett syndrome, autonomic dysregulation in patient populations, and personalised medicine.

The team specifically investigates the role of emotional behavioural autonomic dysregulation (EBAD) in treatment resistance and conducts clinical trials. The CIPPRT team conducted the first clinical trial in Rett syndrome in the UK and is currently involved in other clinical trials in Rett syndrome. Professor Santosh and the team have developed a set of new clinical outcome measures for Rett syndrome and regularly use sensor-based technology to identify clinical biomarkers in rare diseases to help improve the patient care pathway.

We work together with the CIPP clinic at the Michael Rutter Centre at the Maudsley Hospital (part of the South London and Maudsley NHS Foundation Trust), which offers highly specialist pharmacological and psychological assessment and treatment for children with a variety of neuropsychiatric disorders, in the context of complex neurodevelopmental disorders, genetic or neurodegenerative disorders, acquired brain injury, psychotropic-induced side-effects and children experiencing specific medical conditions and terminal illnesses.

The two teams work closely together on both research and clinical duties, continuing the long-standing collaboration between the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s and the South London and Maudsley NHS Foundation Trust.

CIPP Rett Centre

The Centre for Interventional Paediatric Psychopharmacology (CIPP) Rett Centre was established in 2019 by Professor Santosh at the Maudsley Hospital, London and King’s College London. Funded predominantly by parent-based organization Reverse Rett, the CIPP Rett Centre is the world’s first centre for personalised medicine in Rett Syndrome that focuses on developing digital health strategies to monitor and manage patients whilst conducting translational research using the HealthTrackerTM platform, providing holistic specialist care, and conducting clinical trials. The Centre provides access to clinical trials and prepares for the first gene therapy trial to hopefully start in a few years.

At its core, the CIPP Rett Centre focuses on delivering fully holistic, personalised care for those Rett patients who are deemed clinically the most at risk. These include complex cases, where patients have disorders across multiple systems that require careful holistic management, and where patients’ underlying Rett Syndrome causes them not to respond to traditional treatments for their symptoms. This multi-modal aspect of the care pathway allows optimisation of patient-centred care and improvement in clinical outcomes.

Publications

Please see below a list of some of the latest publications featuring Professor Paramala Santosh.
Click 'View all publications' to see the complete list in KCL's Research Portal. 

    Clinical Trials

    Current Clinical Trials

    ANAVEX2-73-RS-002 is a Phase 2, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 18 years and older with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

    Upcoming Clinical Trials

    ANAVEX2-73-RS-003 is a multi-national Phase 2, double-blind, randomized, placebo-controlled, safety, tolerability and efficacy, 12-week dose-titration study of ANAVEX2-73 oral solution in the treatment of patients with RTT between 5 and 17 years of age (inclusive).

    Previous Clinical Trials

    Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms. This was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of multiple doses of sarizotan in patients with Rett syndrome with respiratory abnormalities.

    Publications

    Please see below a list of some of the latest publications featuring Professor Paramala Santosh.
    Click 'View all publications' to see the complete list in KCL's Research Portal. 

      Clinical Trials

      Current Clinical Trials

      ANAVEX2-73-RS-002 is a Phase 2, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 18 years and older with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

      Upcoming Clinical Trials

      ANAVEX2-73-RS-003 is a multi-national Phase 2, double-blind, randomized, placebo-controlled, safety, tolerability and efficacy, 12-week dose-titration study of ANAVEX2-73 oral solution in the treatment of patients with RTT between 5 and 17 years of age (inclusive).

      Previous Clinical Trials

      Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms. This was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of multiple doses of sarizotan in patients with Rett syndrome with respiratory abnormalities.

      Contact us

      Centre for Interventional Paediatric Psychopharmacology Research Team (CIPPRT) 
      Department of Child and Adolescent Psychiatry 
      Institute of Psychiatry, Psychology and Neuroscience 
      King's College London 
      Addiction Sciences Building 
      3rd Floor, PO86 
      1–4 Windsor Walk 
      Denmark Hill 
      London 
      SE5 8BB 

      Leighton McFadden

      Professor Paramala Santosh

      CIPP Rett Centre